Neurodegenerative and neuroinflammatory changes in SOD1-ALS patients receiving tofersen
Neurodegenerative and neuroinflammatory changes in SOD1-ALS patients receiving tofersen
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The initiation of tofersen, a new specific antisense oligonucleotide (ASO) for SOD1 pathology, marked a significant turning point for SOD1-ALS patients. While clinical trials and early access program studies reported a significant reduction in plasma and cerebrospinal fluid (CSF) neurofilament levels, neuroinflammation following prolonged treatment...
Alternative Titles
Full title
Neurodegenerative and neuroinflammatory changes in SOD1-ALS patients receiving tofersen
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7e36eb2f11bc4684bf50641eacbea1e9
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7e36eb2f11bc4684bf50641eacbea1e9
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-025-94984-1
